Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures.
Publication/Presentation Date
1-21-2012
Abstract
In spite of the large number of nutrient-derived agents demonstrating promise as potential chemopreventive agents, most have failed to prove effectiveness in clinical trials. Critical requirements for moving nutrient-derived agents to recommendation for clinical use include adopting a systematic, molecular-mechanism based approach and utilizing the same ethical and rigorous methods such as are used to evaluate other pharmacological agents. Preliminary data on a mechanistic rationale for chemoprevention activity as observed from epidemiological,
Volume
2
Issue
1
ISSN
2167-0870
Published In/Presented At
Kumar, N., Crocker, T., Smith, T., Connors, S., Pow-Sang, J., Spiess, P. E., Egan, K., Quinn, G., Schell, M., Sebti, S., Kazi, A., Chuang, T., Salup, R., Helal, M., Zagaja, G., Trabulsi, E., McLarty, J., Fazili, T., Williams, C. R., Schreiber, F., … Anderson, K. (2012). Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. Journal of clinical trials, 2(1), 1000105. https://doi.org/10.4172/jctr.1000105
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
24533253
Department(s)
Administration and Leadership
Document Type
Article